We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Autologous Stem/Stromal Cells in Neurological Disorders and Disease (NDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03297177
Recruitment Status : Recruiting
First Posted : September 29, 2017
Last Update Posted : January 3, 2018
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:

The study deals with evaluation of safety and efficacy of use of stem/stromal cell isolates from autologous microvasculature in neurological, non-neoplastic disease. Autologous cells are acquired via microcannula aspiration of subdermal fat deposits, isolated through a digestive process, and concentrated via standard centrifugation. The cellular stromal vascular fraction (cSVF) created is neutralized and rinsed to eliminate residual enzymatic molecules.

These cells are suspending in sterile Normal Saline Solution (500cc) and re-administered via an intravenous parenteral route, passed through a standard sterile 150 u (micron) filter in line.

Multiple tracking and questionnaire followup is intended over a 5 year period, with objective and subjective criteria being met. Compilation and analysis of data to be completed after that period.


Condition or disease Intervention/treatment
Dementia Parkinson Altered Behavior in Alzheimer Disease Demyelinating Autoimmune Diseases, CNS Demyelinating Sensorimotor Neuropathy Huntington Disease Corticobasal Degeneration Procedure: Microcannula Harvest Adipose Device: Centricyte 1000 Procedure: Sterile Normal Saline Infusion

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use Of Autologous Stem Cell Use In Neurological Non-neoplastic Disorders And Disease
Actual Study Start Date : December 29, 2017
Estimated Primary Completion Date : January 1, 2023
Estimated Study Completion Date : January 1, 2023


Arms and Interventions

Arm Intervention/treatment
Experimental: Microcannula Harvest Adipose
Acquisition AD-tSVF Via Closed Syringe Microcannula
Procedure: Microcannula Harvest Adipose
Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
Experimental: Centricyte 1000
Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation & concentration in Centricyte 1000 closed system to create AD-cSVF
Device: Centricyte 1000
Closed System, Digestive Isolation & Concentration of AD-cSVF
Experimental: Sterile Normal Saline Infusion
Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
Procedure: Sterile Normal Saline Infusion
Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route


Outcome Measures

Primary Outcome Measures :
  1. Number of participant with adverse events (AE) or severe adverse events (SAE) [ Time Frame: 6 month intervals for up to 5 years ]
    Activities of Daily Living (ADL)


Secondary Outcome Measures :
  1. Neurological Function [ Time Frame: 6 month Intervals for up to 5 years ]
    Change from baseline of deficits of neurologic function identified by patient as impaired prior to study

  2. Neurological Tested Functions [ Time Frame: 6 month interval for up to 5 years ]
    Change from baseline of deficits of neurological function identified by medical provider as impaired prior to study

  3. Magnetic Resonance Imaging (MRI) [ Time Frame: 6 month intervals for up to 5 years ]
    Change in baseline of MRI with and without contrast at 6 month intervals


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented Functional Neurological Damage To Central or Peripheral Nervous System Unlikely To Improve With Present Standard of Care Approaches
  • At least 6 months after onset or diagnosis of disease process
  • Current Medical therapy for the condition is either failing or not tolerated by patient
  • Patient must be capable of interval neurologic exams with investigators or their own neurologic specialists
  • Patient must be capable and determined competent to provide detailed informed consent for study participation
  • In estimation of investigators, that there are minimal or no significant risk of harm to general health or conditions for collection of autologous stem cell collection and use

Exclusion Criteria:

  • Inability of patient to have diagnostic examinations or studies (MRI) to evaluate and document the disease state or unwilling/unable to cooperate with such documentation
  • Patients not medically stable, or whom may have ongoing conditions which increases may place the patient at significant risk of major complications, to be determined by investigator or patient's medical provider or neurologic specialists
  • History of active cancer or ongoing anticancer therapy within six months of such care
  • Women of childbearing age must not be pregnant at the time of treatment, and should refrain from becoming pregnant of at minimum of 3 month after study treatment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03297177


Contacts
Contact: Robert W Alexander, MD, PhD 406.777.5312 rwamd@cybernet1.com
Contact: Nancy L Smith 406.777.5312 nancy@cybernet1.com

Locations
United States, Montana
Global Alliance for Regenerative Medicine-USA Recruiting
Stevensville, Montana, United States, 59870
Contact: Robert Alexander, MD, CMA    406-777-4477    GARM-USA@gmail.com   
Contact: Nancy L Smith, MA,ORT    406.777.5312    nancy@cybernet1.com   
Principal Investigator: Glenn C Terry, MD         
Principal Investigator: Robert W Alexander, MD         
Honduras
GARM Recruiting
Roatan, Hn, Honduras
Contact: Glenn C Terry, MD    +1.765.669.9141    corky3444@gmail.com   
Contact: Heather Terry    17065669141    info@garm.com.hn   
Principal Investigator: Glenn C Terry, MD         
Principal Investigator: Robert W Alexander, MD         
Sponsors and Collaborators
Healeon Medical Inc
Global Alliance for Regenerative Medicine
Regeneris Medical
Investigators
Principal Investigator: Robert W Alexander, MD Regeneris Medical Inc
Principal Investigator: Glenn C Terry Global Alliance for Regenerative Medicine (GARM)
More Information

Publications:

Responsible Party: Robert W. Alexander, MD, FICS, Principal Investigator, Science, Healeon Medical Inc
ClinicalTrials.gov Identifier: NCT03297177     History of Changes
Other Study ID Numbers: GARM NDD
First Posted: September 29, 2017    Key Record Dates
Last Update Posted: January 3, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Annual Summary of Enrolled Cases By All collaborators, principle investigators, or accept sub-investigators

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Huntington Disease
Autoimmune Diseases
Demyelinating Autoimmune Diseases, CNS
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Basal Ganglia Diseases
Chorea
Dyskinesias
Movement Disorders
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Cognition Disorders
Immune System Diseases
Autoimmune Diseases of the Nervous System
Leukoencephalopathies
Demyelinating Diseases